Measuring cancer burden in prostatic needle core biopsies: simplified assessments outperform complex measurements in assessing outcome: evidence to assist pathologist efficiency and minimize datasets
Histopathology · 2023
DOI: 10.1111/his.14886 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, 2023. Verfasst von Daniel M Berney und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, UK. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Cancer Research UK, Myriad Genetics.
Abstract (Originalsprache)
Aims
The optimal method of measuring cancer extent in prostate cancer (PCa) biopsies is unknown. Methods and Results Nine hundred eighty‐one men with clinically localised PCa managed conservatively were reviewed with follow up. The number of positive cores (NPC), the Maximum Cancer Length in a core (MCL), Total Cancer Length (TCL), and percentage of positive cores (%+cores) was calculated and univariate and multivariate analysis performed using prostate‐specific antigen (PSA), T‐stage, and Gleason score. The presence of stromal gaps (SG) was recorded. Univariate models were run where SG made a difference to the MCL. All variables showed significant association with PCa death in univariate models. In multivariate models, incorporating PSA, T‐stage, and Gleason score, only %+cores was a significant predictor of outcome, with a 10% increase in %+cores resulting in a hazard ratio (HR) of 1.07 (likelihood‐ratio test P > Χ 2 = 0.01). There were 120 patients where SG made a difference to the MCL and a total of 20 events in this group. Including SG, on univariate analysis the median MCL was 10 mm and HR was 1.16 ( P = 0.007), not including SG, the median MCL was 6 mm and HR was 1.23 ( P = 6.3 × 10 −4 ). Inclusion or exclusion of SG made no significant difference to TCL as a predictor of outcome.
Conclusion
Cancer extent is a strong predictor of PCa death but only %+cores added to the multivariate model. Expressed as a fraction of NPC/total number of cores, this is the simplest method of assessment, which we favour over more complicated methods in nontargeted biopsies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, UK.
- Department of Cellular Pathology, Barts Health NHS Trust, The Royal London Hospital, London, UK.
- Centre for Prevention, Detection and Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, UK.
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Cellular Pathology, University Hospital of Wales, Cardiff, WLS, UK.
ORCID-Profile: Daniel M Berney, Samson W Fine
Förderung
- NCI NIH HHS
- Cancer Research UK
- Myriad Genetics
Zitieren
APA
Berney, D. M., Finnegan, K., Chu, K., Fine, S. W., Varma, M., Cuzick, J., Beltran, L., & Transatlantic Prostate Group (2023). Measuring cancer burden in prostatic needle core biopsies: simplified assessments outperform complex measurements in assessing outcome: evidence to assist pathologist efficiency and minimize datasets. Histopathology. https://doi.org/10.1111/his.14886
Vancouver
Berney DM, Finnegan K, Chu K, Fine SW, Varma M, Cuzick J, et al. Measuring cancer burden in prostatic needle core biopsies: simplified assessments outperform complex measurements in assessing outcome: evidence to assist pathologist efficiency and minimize datasets. Histopathology. 2023. doi:10.1111/his.14886
BibTeX
@article{Berney2023,
author = {Berney, Daniel M and Finnegan, Kier and Chu, Kim and Fine, Samson W and Varma, Murali and Cuzick, Jack and Beltran, Luis and Transatlantic Prostate Group, Transatlantic Prostate Group},
title = {Measuring cancer burden in prostatic needle core biopsies: simplified assessments outperform complex measurements in assessing outcome: evidence to assist pathologist efficiency and minimize datasets},
journal = {Histopathology},
year = {2023},
doi = {10.1111/his.14886}
}
EUVIMED